Nebivolol/valsartan and Alcohol/Food Interactions
There are 7 alcohol/food/lifestyle interactions with nebivolol / valsartan.
Alcohol (Ethanol) Valsartan
Moderate Drug Interaction
Valsartan and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Alcohol (Ethanol) Nebivolol
Moderate Drug Interaction
Nebivolol and ethanol may have additive effects in lowering your blood pressure. You may experience headache, dizziness, lightheadedness, fainting, and/or changes in pulse or heart rate. These side effects are most likely to be seen at the beginning of treatment, following a dose increase, or when treatment is restarted after an interruption. Let your doctor know if you develop these symptoms and they do not go away after a few days or they become troublesome. Avoid driving or operating hazardous machinery until you know how the medications affect you, and use caution when getting up from a sitting or lying position. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Valsartan Alcohol (Ethanol)
Moderate Drug Interaction
If you are receiving valsartan and nebivolol together with a medication called an ACE inhibitor, you should talk to your doctor to make sure this treatment is appropriate for your condition. When used in the treatment of heart failure, this three drug combination has been associated with increased side effects and an increased rate of death. The reason for this is not clear. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Multivitamins With Minerals Nebivolol
Moderate Drug Interaction
Using nebivolol together with multivitamin with minerals may decrease the effects of nebivolol. Separate the administration times of nebivolol and multivitamin with minerals by at least 2 hours. If your doctor does prescribe these medications together, you may need a dose adjustment or special test to safely use both medications. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Valsartan Multivitamins With Minerals
Moderate Drug Interaction
If you are receiving valsartan and nebivolol together with a medication called an ACE inhibitor, you should talk to your doctor to make sure this treatment is appropriate for your condition. When used in the treatment of heart failure, this three drug combination has been associated with increased side effects and an increased rate of death. The reason for this is not clear. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Valsartan Food
Moderate Food Interaction
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Moderate-to-high dietary intake of potassium, especially salt substitutes, may increase the risk of hyperkalemia in some patients who are using angiotensin II receptor blockers (ARBs). ARBs can promote hyperkalemia through inhibition of angiotensin II-induced aldosterone secretion. Patients with diabetes, heart failure, dehydration, or renal insufficiency have a greater risk of developing hyperkalemia.
MANAGEMENT: Patients should receive dietary counseling and be advised to not use potassium-containing salt substitutes or over-the-counter potassium supplements without consulting their physician. If salt substitutes are used concurrently, regular monitoring of serum potassium levels is recommended. Patients should also be advised to seek medical attention if they experience symptoms of hyperkalemia such as weakness, irregular heartbeat, confusion, tingling of the extremities, or feelings of heaviness in the legs.
References
- (2001) "Product Information. Cozaar (losartan)." Merck & Co., Inc
- (2001) "Product Information. Diovan (valsartan)." Novartis Pharmaceuticals
Nebivolol High Cholesterol (Hyperlipoproteinemia, Hypertriglyceridemia, Sitosterolemia)
Moderate Potential Hazard, Moderate plausibility
beta-blockers - hyperlipidemia
Beta-adrenergic receptor blocking agents (aka beta-blockers) may alter serum lipid profiles. Increases in serum VLDL and LDL cholesterol and triglycerides, as well as decreases in HDL cholesterol, have been reported with some beta-blockers. Patients with preexisting hyperlipidemia may require closer monitoring during beta-blocker therapy, and adjustments made accordingly in their lipid-lowering regimen.
References
- Rossner S, Weiner L (1983) "Atenolol and metoprolol: comparison of effects on blood pressure and serum lipoproteins, and side effects." Eur J Clin Pharmacol, 24, p. 573-7
- Valimaki M, Maass L, Harno K, Nikkila EA (1986) "Lipoprotein lipids and apoproteins during beta-blocker administration: comparison of penbutolol and atenolol." Eur J Clin Pharmacol, 30, p. 17-20
- Disler LJ, Joffe BI, Seftel HC (1988) "Massive hypertriglyceridemia associated with atenolol." Am J Med, 85, p. 586-7
- Harvengt C, Heller FR, Martiat P, Nieuwenhuyze YV (1987) "Short-term effects of beta blockers atenolol, nadolol, pindolol, and propranolol on lipoprotein metabolism in normolipemic subjects." J Clin Pharmacol, 27, p. 475-80
- Darga LL, Hakim MJ, Lucas CP, Franklin BA (1991) "Comparison of the effects of guanadrel sulfate and propranolol on blood pressure, functional capacity, serum lipoproteins and glucose in systemic hypertension." Am J Cardiol, 67, p. 590-6
- Weiner L, Rossner S (1983) "Atenolol 50 mg or metoprolol 200 mg: a comparison of antihypertensive efficacy, side effects and lipoprotein changes." Acta Med Scand, 677, p. 153-7
- Ferrara LA, Marotta T, Scilla A, et al. (1984) "Effect of oxprenolol and metoprolol on serum lipid concentration." Eur J Clin Pharmacol, 26, p. 331-4
- Pasotti C, Capra A, Fiorella G, et al. (1982) "Effects of pindolol and metoprolol on plasma lipids and lipoproteins." Br J Clin Pharmacol, 13, s435-9
- Carlson LA, Ribacke M, Terent A (1987) "A long-term study on the effect of pindolol on serum lipoproteins: a preliminary report." Br J Clin Pharmacol, 24, s61-2
- Samuel P, Chin B, Schoenfeld BH, et al. (1987) "Comparison of the effect of pindolol versus propranolol on the lipid profile in patients treated for hypertension." Br J Clin Pharmacol, 24, s63-4
- Terent A, Ribacke M, Carlson LA (1989) "Long-term effect of pindolol on lipids and lipoproteins in men with newly diagnosed hypertension." Eur J Clin Pharmacol, 36, p. 347-50
- Sasaki J, Saku K, Ideishi M, et al. (1989) "Effects of pindolol on serum lipids, apolipoproteins, and lipoproteins in patients with mild to moderate essential hypertension." Clin Ther, 11, p. 219-24
- Szollar LG, Meszaros I, Tornoci L, et al. (1990) "Effect of metoprolol and pindolol monotherapy on plasma lipid- and lipoprotein-cholesterol levels (including the HDL subclasses) in mild hypertensive males and females." J Cardiovasc Pharmacol, 15, p. 911-7
- Leren P, Foss PO, Nordvik B, Fossbakk B (1988) "The effect of enalapril and timolol on blood lipids." Acta Med Scand, 223, p. 321-6
- (2002) "Product Information. Sectral (acebutolol)." Wyeth-Ayerst Laboratories
- (2002) "Product Information. Tenormin (atenolol)." ICN Pharmaceuticals Inc
- (2002) "Product Information. Normodyne (labetalol)." Schering Corporation
- (2002) "Product Information. Trandate (labetalol)." Glaxo Wellcome
- (2002) "Product Information. Corgard (nadolol)." Bristol-Myers Squibb
- (2001) "Product Information. Inderal (propranolol)." Wyeth-Ayerst Laboratories
- (2001) "Product Information. Blocadren (timolol)." Merck & Co., Inc
- Northcote RJ, Packard CJ, Ballantyne D (1986) "The effect of sotalol on plasma lipoproteins and apolipoproteins." Clin Chim Acta, 158, p. 187-91
- Lehtonen A, Hietanen E, Marniemi J, Peltonen P, Nikkila EA (1983) "Effect of sotalol withdrawal on serum lipids and lipoprotein lipase activity." Int J Clin Pharmacol Ther Toxicol, 21, p. 73-6
- (2001) "Product Information. Cartrol (carteolol)." Abbott Pharmaceutical
- (2001) "Product Information. Kerlone (betaxolol)." Searle
- (2001) "Product Information. Lopressor (metoprolol)." Novartis Pharmaceuticals
- (2001) "Product Information. Betapace (sotalol)." Berlex Laboratories
- (2001) "Product Information. Zebeta (bisoprolol)." Lederle Laboratories
- Safran AB, Simona F, Sansonetti A, Pometta D, James R (1994) "Effects of ocular carteolol and timolol on plasma high-density lipoprotein cholesterol level." Am J Ophthalmol, 117, p. 683
- (2001) "Product Information. Visken (pindolol)." Sandoz Pharmaceuticals Corporation
- Clucas A, Miller N (1988) "Effects of acebutolol on the serum lipid profile." Drugs, 36 Suppl 2, p. 41-50
- (2001) "Product Information. Levatol (penbutolol)." Reed and Carnrick
- Kasiske BL, Ma JZ, Kalil RS, Louis TA (1995) "Effects of antihypertensive therapy on serum lipids." Ann Intern Med, 122, p. 133-41
- Lind L, Pollare T, Berne C, Lithell H (1994) "Long-term metabolic effects of antihypertensive drugs." Am Heart J, 128, p. 1177-83
- Sasaki J, Kajiyama G, Kusukawa R, Mori H, Koga S, Takagi R, Tanaka N, Ogawa N, Arakawa K (1994) "Effect of bevantolol and propranolol on serum lipids in patients with essential hypertension." Int J Clin Pharmacol Ther, 32, p. 660-4
- (2001) "Product Information. Coreg (carvedilol)." SmithKline Beecham
- Lithell H, Andersson PE (1997) "Metabolic effects of carvedilol in hypertensive patients." Eur J Clin Pharmacol, 52, p. 13-7
- Gordon NF, Scott CB, Duncan JJ (1997) "Effects of atenolol versus enalapril on cardiovascular fitness and serum lipids in physically active hypertensive men." Am J Cardiol, 79, p. 1065-9
- (2007) "Product Information. Bystolic (nebivolol)." Forest Pharmaceuticals
Nebivolol/valsartan drug interactions
There are 574 drug interactions with nebivolol / valsartan.
Nebivolol/valsartan disease interactions
There are 26 disease interactions with nebivolol / valsartan which include:
- diabetes
- angioedema
- hypotension
- bradyarrhythmia/AV block
- cardiogenic shock/hypotension
- CHF
- diabetes
- hypersensitivity
- ischemic heart disease
- PVD
- hepatic impairment
- CHF
- hyperkalemia
- renal artery stenosis
- renal impairment
- cerebrovascular insufficiency
- glaucoma
- hyperlipidemia
- hyperthyroidism
- myasthenia gravis
- pheochromocytoma
- psoriasis
- tachycardia
- asthma/COPD
- renal impairment
- renal/liver disease
More about nebivolol / valsartan
- nebivolol/valsartan consumer information
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy
- Drug class: miscellaneous antihypertensive combinations
- En español
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.